Video Insights
Advertisement
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on ARANOTE, Metacure, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CREST, ENLIGHTED, and more.
Dr. Brown breaks down the CREST trial results in high-risk NMIBC, highlighting the benefits of combining sasanlimab with BCG.
Dr. Brown discusses the latest TAR-200 data from the SunRISe-1 trial in BCG-unresponsive NMIBC, highlighting CR rates.
Drs. Wulff-Burchfield and Beckermann offer perspective on how patient-driven science is shaping QOL measurement.
Drs. Wulff-Burchfield and Beckermann share how they help GU patients make informed, personalized treatment decisions.
Drs. Wulff-Burchfield and Beckermann discuss how GU oncologists can build trust and deepen patient connections.
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Drs. Swami and Ciuro discuss real-world data that indicates a shift in mHSPC treated with intensified therapy since 2023.
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
Dr. Avudaiappan compares radical prostatectomy with dose-escalated radiation with ADT for the treatment of prostate cancer.
At the AUA 2025 Annual Meeting, Dr. Guerrero-Ramos highlights the first results from Cohort 4 of SunRISe-1.
Dr. Shore highlights post hoc analyses of ultra-low PSA responses and their correlation with outcomes in the ARANOTE study.
Results of the CREST study show that sasanlimab plus BCG improves EFS compared with BCG alone in high-risk NMIBC.
Drs. Chang and Joyce consider the role that N-803 now plays within the treatment paradigm for BCG-unresponsive bladder CIS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.